Nanomerics Update

Development Agreement to Tackle Glaucoma

[20-Mar-2017] Nanomerics has entered into a development agreement with California based NEMUS Bioscience, Inc. (OTCQB: NMUS), to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma.

“Historically, it has been challenging to formulate hydrophobic, or fat-soluble, cannabinoid molecules for efficient and predictable entry into the body, especially the eye,” stated Brian Murphy, M.D., M.B.A., Nemus CEO and Chief Medical Officer. “Nemus has found the MET technology profile to be supportive of the work performed to-date using the more hydrophilic THCVHS which was designed to cross physiologic barriers more efficiently. Developing this formulation is an important step before conducting human studies.“ Read more ...

Ophthalmology SAB Strengthened

[26-Feb-2017] Dr Sajjad Ahmad is a consultant ophthalmologist/corneal surgeon at Moorfields Eye Hospital and honorary senior clinical lecturer at the UCL Institute of Ophthalmology. His clinical expertise is in ocular surface and corneal inflammatory disease and ocular surface/corneal/anterior segment reconstruction of the eye. He has developed a culture system for human corneal epithelial stem cells that has been successfully used in clinical trials nationally. Read more...

North American Rights to NM133 Licensed

[13-Jan-2017] Nanomerics today announced that it has licensed the North American rights to NM133 for the treatment of dry eye to IACTA Pharmaceuticals.

Professor Andreas Schatzlein, CEO of Nanomerics, said, “Nanomerics believes IACTA is the ideal North American licensee for NM133. The need for better medicines remains undiminished and drugs need to be used to their full potential to deliver patient benefit. Nanomerics’ Molecular Envelope Technology (MET) is engineered at the nanoscale to efficiently deliver drugs for a variety of applications. NM133 is a product in which many of the MET attributes are being exploited to bring tangible benefits to those suffering from dry eye disease.”

Damon Burrows, Founder and CEO of IACTA Pharmaceuticals, said, “We are enthusiastic about partnering with Nanomerics and are grateful that they have placed their trust in us as their North American licensee. We strongly believe in the promise of MET technology for the treatment of a range of conditions including dry eye.” Read more...